Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
. Is one technology clinically better than another
Advanced malignant melanoma has seven primarily drug treatments. Health technology assessments have been used to compare the effectiveness of each drug. The primary considerations are the overall survival rate, quality of life, cost-effectiveness, adverse side-effects, and the quality of data used to properly ascertain the drug effectiveness (Pike, 2015). The seven drugs subject the HTA are listed below:
a. Cobimetinib
b. Dabrafenib
c. Ipilimumab
d. Nivolumab
e. Pembrolizumab
f. Trametinib
g. Vemurafenib
2. Are there differences in safety profiles of available technology choices?
Yes, there a stark difference between safety profiles. Patients, without treatment have very poor prognosis with survival rates of 12% of men and 25% for women. In cases where treatment of Trametinib was used safety and survival rates increased roughly 40% (Robert, 2015)
3. What is the cost of the technology?
Nivolumab was the most cost-effective treatment costing $24,483 per quality...
The cost effectiveness of the treatment has declined every year for the past decade as new advances in administration and number of treatments has declined. In 2010, the cost was roughly $37,000 per quality adjusted life year.
4. Who will use the technology?
Those who will use the technology are suffering for incidences of malignant melanoma. The technology can be adopted by patients around the world irrespective of location. The studies conducted focused primarily on Hungary and the European Union.
5. Will the technology result in improved patient outcomes?
Yes, the technology will improve patient outcomes as it relates to survival rate, quality of life and cost-effectiveness of treatments. The most important improvement is related to patient outcomes as the survival rates prior to treatment breakthroughs were very low. As noted above the effectiveness has increase roughly 40%.
6. Health Technology Assessment Topic
My topic will be Melanoma. The focus will…
References
1. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014;371(20):1877-1888.
2. Pike, E., Torkilseng, E. B., Saeterdal, I., Jimenez, E., Odgaard-Jensen, J., Harboe, I., & Klemp, M. (2015). A Health Technology Assessment of the New Drugs for Inoperable or Metastatic Malignant Melanoma Patients. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH).
3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):311-319
Healthcare Technology One of the main barriers to implementing such a plan as described above is the expense of doing so; but that is true only if one looks at the immediate cash expense. The savings created by providing medical personnel with their own Personal Digital Assistant far outweighs the cash necessary to make such a venture a reality. Realistically speaking, however, there will be plenty of medical entities throughout the
In respects, it could also reduce lawsuit expense when patients want to sue because of the wrong medication is given or harm is done in the process of medication administration. "We often resist the new way of doing things..." (Thede, 2009, Sept). Behaviors are often aimed at relieving the pressures from change rather than advancing a new approach to the way we do things. We tend to view change as
The modern healthcare environment has experienced tremendous changes in the past few decades because of the increased need to enhance patient outcomes and safety. These changes have contributed to the adoption of technology, which has transformed modern communication. Technology adoption in the healthcare setting has been geared towards enhancing patient care processes and systems in order to realize better patient outcomes. This adoption has involved the development of several technologies
Melanoma/Amelanotic Melanoma is a malignant tumor of the melanocytes, cells that are derived from the neural crest, and although most melanomas arise in the skin, some may also arise from mucosal surfaces or other sites to which neural crest cells migrate (General pg). More than half of the cases arise in apparently normal areas of the skin and occur predominantly in adults (General pg). In women it occurs more commonly on
Melanoma. Who is at risk, and how can this deadly cancer be prevented? 1. Abstract Melanoma cancer has been identified and rapidly increasing over the years as the deadliest skin cancer amongst young adults with women being at a higher risk than men. The purpose of this research is to attain knowledge on the risk involving this cancer, look into preventative ways to minimize the exposure to this type of cancer, and